Formulation and Evaluation of Clarithromycin Co-Crystals Tablets Dosage Forms to Enhance the Bioavailability
Pinki Rajbhar, Atul K. Sahu, S. S. Gautam, Raj K. Prasad, V. Singh, S. K. Nair
Clarithromycin is a semi-synthetic macrolide antibiotic which inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. In this work BCS Class II drug Clarithromycin is used as a model drug, which is having poor solubility but high permeability. A pharmaceutical co-crystal is a single crystalline solid that incorporates two neutral molecules, one being an active pharmaceutical ingredient (API) and the other a co-crystal former. Co-crystals of Clarithromycin were prepared using co-crystal former (urea), with method of preparation (solvent evaporation). In the present study, Clarithromycin co-crystals tablets were prepared and evaluated in order to improve the dissolution by enhancing the solubility of Clarithromycin using urea co crystals to improve the bioavailability. In this work, the wet granulation method was attempted for formulation of conventional tablets of Clarithromycin. The Clarithromycin tablets are available in 250mg- 500mg, doses in market. Dose of 250mg was selected for the present research work.
Zone of Inhibition (cm) of F4 and Marketed Drug
How to cite this article:
Pinki Rajbhar, Atul K. Sahu, S. S. Gautam, Raj K. Prasad, V. Singh, S. K. Nair. Formulation and Evaluation of Clarithromycin Co-Crystals Tablets Dosage Forms to Enhance the Bioavailability. Pharma Innovation 2016;5(6):05-13.